HAMP and type 2 diabetes mellitus: In patients with type 2 diabetes and CKD, a post hoc analysis of the DELIGHT trial reported that changes in TSAT and transferrin over 24 weeks of treatment with dapagliflozin correlated with changes in urinary and plasma interleukin-6, an inflammatory cytokine that regulates hepcidin expression [23, 24].